Spain's CNMC opens a sanctioning case against five healthcare companies over a Xunta tender
The CNMC opens case S/0019/25 against five companies and one executive over possible anticompetitive practices in a Xunta de Galicia tender.

Spain's National Commission for Markets and Competition (CNMC) announced on 13 November 2026 that it has opened sanctioning proceedings against five companies and one executive in the private healthcare sector. According to its press release, the case, numbered S/0019/25, examines possible anticompetitive practices affecting a public tender by the Xunta de Galicia. The CNMC itself stresses that opening the case does not prejudge the outcome of the investigation. This article describes what the regulator has said and does not attribute liability to any party.
Who is under investigation
The companies are Gerosalud, a healthcare management firm; the hospital groups Ribera Salud, Recoletas Salud and HM; and Hospital Concheiro. The CNMC also includes one of Gerosalud's executives. The release gives neither the executive's name nor the exact role. In sanctioning proceedings, being named as an investigated party means the authority has opened the formal investigation phase. It is not a finding of guilt or a final decision.
The conduct under review
The release describes two lines of inquiry. The first is a possible agreement or concerted practice. The CNMC is analysing whether Ribera Salud, Recoletas Salud, HM and Hospital Concheiro agreed, exclusively with Gerosalud, how to provide healthcare services linked to a group sports-accident insurance policy put out to tender by the Xunta de Galicia. According to the regulator, that possible arrangement would have prevented the insurer originally awarded the contract from formalising it. As a result, the tender would have gone to a second company, to Gerosalud's benefit. If confirmed, such conduct would breach Article 1 of Law 15/2007 on the Defence of Competition (LDC), which prohibits agreements and concerted practices that restrict competition.
The second line is a possible abuse of a dominant position. The CNMC is investigating whether the Ribera Salud Group and the Recoletas Salud Group refused, without justification, to supply an essential input. The release adds that, if proven, this conduct could infringe Article 2 of the LDC. The conditional tone matters: the release speaks of "possible" practices and of what "would have" happened, not of proven facts.
The November 2025 inspections
The case did not come out of nowhere. The CNMC recalls that between 18 and 21 November 2025 it inspected the premises of several companies in different parts of Spain, in cooperation with the Galician Competition Commission. That action, announced at the time in a separate press release, was a step before a possible case. Opening the case, almost a year later, is the formal step now announced.
Deadlines and next steps
The release says a maximum period of 24 months now applies for the case to be resolved. This is a limit on the proceedings, not a forecast of a decision date. The release mentions no amounts, so this article does not estimate sanctions.
Background: what the CNMC said in November 2025
The CNMC release of 27 November 2025 announced the inspections as a preliminary step. According to that text, the CNMC was then investigating possible agreements or concerted practices between companies operating in private healthcare provision and healthcare consulting, and a possible abuse of dominant position by some private healthcare providers, with a possible infringement of Articles 1.1 and 2 of the LDC. The release named no company and specified that the inspections did not prejudge the outcome or the guilt of the inspected companies. They were carried out together with the regional competition authority of one of the territories where the investigated companies are located.
There is a difference between the two releases. The 2025 one spoke of a broad market, private healthcare provision and healthcare consulting, while the 2026 one narrows the case to a Xunta de Galicia tender and a group sports-accident insurance policy. It is therefore unwise to assume that everything investigated in 2025 is covered by case S/0019/25, or that the case exhausts the investigation. The 2026 release does not clarify this. Nor does it expressly link the 2025 inspections to specific companies beyond saying that it inspected "several" premises.
The general penalty framework
The 2025 release recalled that agreements between competitors are a very serious infringement of competition law, which can carry fines of up to 10% of the infringing companies' total turnover in the financial year preceding the fine. That is a general legal ceiling the CNMC cited then for that type of conduct. The 2026 release does not repeat the figure or apply it to any investigated party, so it cannot be presented as a forecast of a sanction in this case. For abuse of a dominant position, the releases consulted do not give a different limit.
What Articles 1 and 2 of the LDC prohibit
The CNMC release places the conduct under Articles 1 and 2 of Law 15/2007. According to its consolidated text, Article 1.1 prohibits any collective agreement, decision or recommendation, or concerted or consciously parallel practice, that has as its object, produces or may produce the effect of preventing, restricting or distorting competition in all or part of the national market. The list of examples, introduced by "in particular", includes fixing prices or other commercial conditions, limiting or controlling production, distribution, technical development or investment, sharing markets or sources of supply, applying unequal conditions to equivalent transactions, and making contracts subject to supplementary obligations. Article 1.2 declares void any prohibited agreement not covered by the exemptions in the law.
Those exemptions exist. Article 1.3 excludes from the prohibition agreements and practices that help improve production or the marketing and distribution of goods and services, or promote technical or economic progress, without need for a prior decision, provided three conditions are met: consumers or users get a fair share of the benefits, no restrictions are imposed that are not indispensable for those aims, and the firms are not enabled to eliminate competition in respect of a substantial part of the products or services concerned. Article 1.4 also covers the categories protected by EU regulations. That a practice is under investigation does not mean it cannot qualify for an exemption; the CNMC release does not say that any has been examined or invoked.
Article 2.1 prohibits the abusive exploitation, by one or more firms, of a dominant position in all or part of the national market. Article 2.2 gives examples, among them imposing unfair prices or conditions, limiting production or distribution to the unjustified detriment of firms or consumers, an unjustified refusal to meet purchase demands for products or requests for services, unequal conditions for equivalent transactions, and making contracts subject to supplementary obligations. The release speaks of an unjustified refusal to supply an essential input, but does not say under which point of Article 2.2 the CNMC places that conduct, and nothing in it shows that it does.
Why it matters to law firms and their clients
For advisers to healthcare operators, insurers or bidders in public procurement, the case illustrates three practical points. They are stated cautiously because the case is at an early stage:
- Tenders and group insurance. The CNMC is examining how coordination between providers could affect the formalisation of an awarded contract. Compliance teams may want to review what contacts their clients keep with other providers during a procurement procedure.
- Access to essential inputs. The second line puts the spotlight on refusals to supply by operators that may hold a dominant position. The assessment will depend on what counts as an essential input and whether the refusal had a justification, questions the release does not develop.
- Cooperation between authorities. Working with the Galician Competition Commission shows how the national and regional regulators coordinate on inspections.
What the release does not say
The press release is an information document. The CNMC warns that it is not official and does not bind the authority. It does not name the insurer originally awarded the contract or the second company that received it, and it gives no tender value. Nor does it say which centres of Hospital Concheiro or the hospital groups take part in the specific services, or anticipate sanctions. Any view on liability would be premature.
Related reading
Other CNMC cases and actions we have covered: sanctioning proceedings against Apple and Amazon, proceedings against Lyntia over dark fibre, inspections in energy markets. They are different cases in different sectors and add no evidence about this one.
Dates and sources
The opening of the case was announced on 13 November 2026, more than 48 hours before this 16 November edition. It is not a same-day story: it summarises a press release from three days earlier. The main source is the CNMC press release. Europa Press coverage of the same day matches it on the parties and the Galician context, but this article relies on the official release for the data and legal references. The references to Law 15/2007 are those cited in the release itself.
Fuentes
- Source. Accessed 16 November 2026.
- Source. Accessed 16 November 2026.
- Source. Accessed 16 November 2026.
- Source. Accessed 16 November 2026.
- Source. Accessed 16 November 2026.
The specific data in this article come from the official sources cited.


